Trial Information

Summary: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B [GS-US-174-0102]

This is a research study involving an experimental drug named tenofovir DF for the treatment of the chronic hepatitis B virus (HBV). The purpose of this study is to compare the safety and the effectiveness of tenofovir DF (TDF) to that of adefovir dipivoxil (ADV) in patients chronically infected with HBV who have never taken an oral treatment for their HBV. Participants will take TDF + placebo or ADV + placebo.
Participation will last about 48 weeks and there will be about 14 clinic visits.
All study procedures and medications are provided at no cost to you.
Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are 18-69 years old
-have been diagnosed with chronic HBV infection for at least 6 months

You will not be able to participate if you
-are pregnant or breastfeeding
-are coinfected with HIV, HCV or HDV
-have taken an oral treatment for your HBV
-have received an organ or bone marrow transplant

If you would like to learn more about participating in this study, please send an e-mail message using the form below.